Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.

Christine M Minnar Paul L Chariou Lucas A Horn Kristin C Hicks Claudia Palena Jeffrey Schlom Sofia R Gameiro

Published in: Journal for immunotherapy of cancer (2022)

Our findings provide a rationale for combining the tumor-targeting NHS-IL12 with the histone deacetylase inhibitor entinostat in the clinical setting for patients unresponsive to αPD-1/αPD-L1 and/or with innate deficiencies in tumor MHC-I, APM expression, and IFN-γ signaling.

Keyphrases

histone deacetylase
immune response
end stage renal disease
poor prognosis
newly diagnosed
chronic kidney disease
clinical trial
patient safety
prognostic factors
dendritic cells
patient reported outcomes
long non coding rna
binding protein